Proteomics International Laboratories (ASX:PIQ) launched its PromarkerD blood test at the 85th Scientific Sessions of the American Diabetes Association in Illinois, according to a Friday filing with the Australian bourse.
The diagnostic tool is designed to predict the onset of diabetic kidney disease up to four years in advance in individuals with type 2 diabetes, the filing said.
The test, initially available in California, will be provided by the company's Clinical Laboratory Improvement Amendment-certified reference laboratory, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.